ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHYHara, Chikako MD; Sawa, Miki MD; Sayanagi, Kaori MD; Nishida, Kohji MDRetina: January 2016 - Volume 36 - Issue 1 - p 37–45 doi: 10.1097/IAE.0000000000000767 Original Study Abstract In Brief Author Information Purpose: To evaluate the 1-year results of intravitreal aflibercept injections for polypoidal choroidal vasculopathy based on indocyanine green angiography findings. Methods: Twenty-nine eyes with treatment-naive polypoidal choroidal vasculopathy treated with intravitreal aflibercept injections and followed longer than 1 year were retrospectively reviewed. The best-corrected visual acuity, optical coherence tomography findings, and polypoidal lesions in indocyanine green angiography were evaluated. Results: The mean number of injections through 1 year was 3.9 ± 1.9 (range: 1–8). Fourteen eyes (48%) were received no additional injections because of no recurrence of exudative change after the first loading dose. The mean best-corrected visual acuity levels at 6 months and 1 year significantly improved, and the mean central retinal thickness significantly decreased at all observation points from the baseline. At 3 months, the polypoidal lesions completely resolved in 19 (66%) eyes. At 1 year, the complete resolution of polypoidal lesions was seen in 4 of 10 eyes with persistent polypoidal lesions at 3 months. However, polypoidal lesions recurred at 1 year in 5 of 19 eyes (26%) with complete resolution of polypoidal lesions at 3 months. Conclusion: Aflibercept is effective for the eyes with treatment-naive polypoidal choroidal vasculopathy to achieve the resolution of polypoidal lesions. The athors need to carefully observe the eyes after confirming complete resolution of polypoidal lesion because of recurrent polyps seen in one-quarter of the study eyes. In this study about efficacy of aflibercept for 29 eyes with treatment-naive polypoidal choroidal vasculopathy for 1 year, no recurrence of exudative change after the first loading dose was seen in 48% of eyes. The polypoidal lesions responded at 3 months in total 80% of eyes but recurred in 26% of eyes at 1 year. Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan. Reprint requests: Chikako Hara, MD, Department of Ophthalmology, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan; e-mail: firstname.lastname@example.org None of the authors have any financial/conflicting interests to disclose. © 2016 by Ophthalmic Communications Society, Inc.